AstraZeneca coronavirus shot could be ready for large-scale vaccinations as early as this year.
The U.K. drugmaker is poised to unveil vaccine test results by year-end even after trials were slightly delayed over the summer as infection rates slowed in the northern hemisphere. Astra and the University of Oxford are keeping the vaccine in a frozen bulk state to preserve its shelf life while they await final test results.
“At the end of the day, we don’t yet know if the vaccine works,” Chief Executive Officer Pascal Soriot said, during an interview with Bloomberg. “Many questions remain, such as whether it will show results for everyone and for how long. “We would hope that large-scale vaccinations would be possible starting in January next year — possibly even December.”
Soriot’s remarks come a day after Kate Bingham, chair of the U.K. Vaccine Taskforce, said only 4 million doses of the shot would be available by the end of the year, far fewer than the 30 million that were due to be ready by September. AstraZeneca said it’s confident it can begin supplying hundreds of millions of doses on a “rolling basis” once a shot is cleared.
Soriot said the world needs several vaccines and that Astra studies conducted in the U.K. and Brazil kept progressing well even as the U.S. one suffered a halt. It’s possible the U.S. Food and Drug Administration will want to wait for the results of the local trial before reviewing the product, he said.
The FDA “may want to wait for the results of the U.S. study or they may review our international program and give us an emergency approval on that basis,” Soriot said. “It will be up to regulators in individual countries to decide.”
Astra has said it will sell the vaccine for about $4 to $5 depending on local manufacturing charges. The company said recently it would add as much as 20% to cover manufacturing costs to avoid any material impact on its finances. Astra is incurring a bill in excess of $1 billion globally for expenses including clinical development, Soriot said.